Viatris rises after quarterly results beat

Shares of generic drugmaker Viatris VTRS.O rise as much as 10.1% to a near two-month high of $9.47

VTRS posts Q1 adj. profit of 50 cents per share, compared with analysts' estimate of 49 cents per share, according to data compiled by LSEG

Co reports Q1 revenue of $3.25 billion vs estimates of $3.23 billion

VTRS expects 2025 adj. profit between $2.12 and $2.26 per share, compared with estimate of $2.59 per share

*Co says "it continues to explore ways to optimize the flexibility of our global network, including the potential to increase our manufacturing capacity in the U.S." as a way to mitigate potential tariffs

Separately, VTRS also says its fast-acting form of generic pain drug meloxicam met the main goals of two late-stage studies, and a lower dose version of its birth control patch, called Xulane, also met all the main goals of a late-stage study

Including session's move, stock down 25.3%